Cargando…

Hypotonic intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in mice.

The intraperitoneal (i.p.) administration of cisplatin (CDDP) is one of the most effective therapies for cancers that are confined to the abdominal cavity. However, the effect of fluid osmolarity on the therapeutic efficacy of i.p. administration of CDDP has not been well established. In the current...

Descripción completa

Detalles Bibliográficos
Autores principales: Kondo, A., Maeta, M., Oka, A., Tsujitani, S., Ikeguchi, M., Kaibara, N.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1996
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074519/
https://www.ncbi.nlm.nih.gov/pubmed/8630273
_version_ 1782137984228786176
author Kondo, A.
Maeta, M.
Oka, A.
Tsujitani, S.
Ikeguchi, M.
Kaibara, N.
author_facet Kondo, A.
Maeta, M.
Oka, A.
Tsujitani, S.
Ikeguchi, M.
Kaibara, N.
author_sort Kondo, A.
collection PubMed
description The intraperitoneal (i.p.) administration of cisplatin (CDDP) is one of the most effective therapies for cancers that are confined to the abdominal cavity. However, the effect of fluid osmolarity on the therapeutic efficacy of i.p. administration of CDDP has not been well established. In the current study, hypotonic (154 mosmol 1-1), isotonic (308 mosmol 1-1) and hypertonic (616 mosmol 1-1) solutions of CDDP were prepared for an evaluation of their therapeutic efficacy in an experimental system. After i.p. administration, uptake of CDDP in vivo by tumor cells in hypotonic solution was significantly greater than in isotonic or hypertonic solution. The 50% lethal dose (LD50) value of CDDP in hypotonic solution (12.1 mg kg(-1)) was lower than that in isotonic solution (16.9 mg kg(-1)) and than that in hypertonic solution (28.6 mg kg(-1)). However, when a dose equal to one-half of the LD50 was administered in each solution to mice with i.p. tumours, survival of mice given the CDDP in hypotonic solution was significantly prolonged as compared with the survival of the other mice. These results demonstrate that the therapeutic efficacy of i.p. CDDP in mice is augmented when the drug is administered in hypotonic solution.
format Text
id pubmed-2074519
institution National Center for Biotechnology Information
language English
publishDate 1996
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20745192009-09-10 Hypotonic intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in mice. Kondo, A. Maeta, M. Oka, A. Tsujitani, S. Ikeguchi, M. Kaibara, N. Br J Cancer Research Article The intraperitoneal (i.p.) administration of cisplatin (CDDP) is one of the most effective therapies for cancers that are confined to the abdominal cavity. However, the effect of fluid osmolarity on the therapeutic efficacy of i.p. administration of CDDP has not been well established. In the current study, hypotonic (154 mosmol 1-1), isotonic (308 mosmol 1-1) and hypertonic (616 mosmol 1-1) solutions of CDDP were prepared for an evaluation of their therapeutic efficacy in an experimental system. After i.p. administration, uptake of CDDP in vivo by tumor cells in hypotonic solution was significantly greater than in isotonic or hypertonic solution. The 50% lethal dose (LD50) value of CDDP in hypotonic solution (12.1 mg kg(-1)) was lower than that in isotonic solution (16.9 mg kg(-1)) and than that in hypertonic solution (28.6 mg kg(-1)). However, when a dose equal to one-half of the LD50 was administered in each solution to mice with i.p. tumours, survival of mice given the CDDP in hypotonic solution was significantly prolonged as compared with the survival of the other mice. These results demonstrate that the therapeutic efficacy of i.p. CDDP in mice is augmented when the drug is administered in hypotonic solution. Nature Publishing Group 1996-05 /pmc/articles/PMC2074519/ /pubmed/8630273 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Kondo, A.
Maeta, M.
Oka, A.
Tsujitani, S.
Ikeguchi, M.
Kaibara, N.
Hypotonic intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in mice.
title Hypotonic intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in mice.
title_full Hypotonic intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in mice.
title_fullStr Hypotonic intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in mice.
title_full_unstemmed Hypotonic intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in mice.
title_short Hypotonic intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in mice.
title_sort hypotonic intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in mice.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074519/
https://www.ncbi.nlm.nih.gov/pubmed/8630273
work_keys_str_mv AT kondoa hypotonicintraperitonealcisplatinchemotherapyforperitonealcarcinomatosisinmice
AT maetam hypotonicintraperitonealcisplatinchemotherapyforperitonealcarcinomatosisinmice
AT okaa hypotonicintraperitonealcisplatinchemotherapyforperitonealcarcinomatosisinmice
AT tsujitanis hypotonicintraperitonealcisplatinchemotherapyforperitonealcarcinomatosisinmice
AT ikeguchim hypotonicintraperitonealcisplatinchemotherapyforperitonealcarcinomatosisinmice
AT kaibaran hypotonicintraperitonealcisplatinchemotherapyforperitonealcarcinomatosisinmice